{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:14:07Z","timestamp":1794352447002,"version":"4.9.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202856"],"award-info":[{"award-number":["82202856"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021M702754"],"award-info":[{"award-number":["2021M702754"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Xuzhou Municipal Health Commission","award":["XWKYHT20210589"],"award-info":[{"award-number":["XWKYHT20210589"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06115-z","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T22:31:41Z","timestamp":1737585101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiannan","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengsong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhua","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"6115_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"6115_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/ng0495-401","volume":"9","author":"T Visakorpi","year":"1995","unstructured":"Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9:401\u20136.","journal-title":"Nat Genet"},{"key":"6115_CR3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;162:454.","journal-title":"Cell"},{"key":"6115_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33\u20139.","journal-title":"Nat Med"},{"key":"6115_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nm.4053","volume":"22","author":"A Kumar","year":"2016","unstructured":"Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016;22:369\u201378.","journal-title":"Nat Med"},{"key":"6115_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4405","volume":"355","author":"CR Ritch","year":"2016","unstructured":"Ritch CR, Cookson MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016;355: i4405.","journal-title":"BMJ"},{"key":"6115_CR7","doi-asserted-by":"publisher","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","volume":"7","author":"A Romanel","year":"2015","unstructured":"Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015;7:312re10.","journal-title":"Sci Transl Med"},{"key":"6115_CR8","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","volume":"28","author":"V Conteduca","year":"2017","unstructured":"Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. 2017;28:1508\u201316.","journal-title":"Ann Oncol"},{"key":"6115_CR9","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.27159","volume":"6","author":"L Cato","year":"2017","unstructured":"Cato L, Neeb A, Sharp A, Buzon V, Ficarro SB, Yang L, et al. Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. Elife. 2017;6: e27159.","journal-title":"Elife"},{"key":"6115_CR10","first-page":"3550","volume":"61","author":"MJ Linja","year":"2001","unstructured":"Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001;61:3550\u20135.","journal-title":"Cancer Res"},{"key":"6115_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","volume":"15","author":"K Fizazi","year":"2014","unstructured":"Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014;15:1147\u201356.","journal-title":"Lancet Oncol"},{"key":"6115_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med"},{"key":"6115_CR13","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:1755\u20136.","journal-title":"N Engl J Med"},{"key":"6115_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"6115_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(15)70113-0","volume":"16","author":"Y Loriot","year":"2015","unstructured":"Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16:509\u201321.","journal-title":"Lancet Oncol"},{"key":"6115_CR16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"6115_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.eururo.2017.01.011","volume":"72","author":"B De Laere","year":"2017","unstructured":"De Laere B, van Dam PJ, Whitington T, Mayrhofer M, Diaz EH, Van den Eynden G, et al. Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns. Eur Urol. 2017;72:192\u2013200.","journal-title":"Eur Urol"},{"key":"6115_CR18","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","volume":"69","author":"Z Guo","year":"2009","unstructured":"Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69:2305\u201313.","journal-title":"Cancer Res"},{"key":"6115_CR19","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","volume":"72","author":"R Hu","year":"2012","unstructured":"Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012;72:3457\u201362.","journal-title":"Cancer Res"},{"key":"6115_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","volume":"73","author":"Y Li","year":"2013","unstructured":"Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73:483\u20139.","journal-title":"Cancer Res"},{"key":"6115_CR21","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med"},{"key":"6115_CR22","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-16-0205","volume":"22","author":"LB Guedes","year":"2016","unstructured":"Guedes LB, Morais CL, Almutairi F, Haffner MC, Zheng Q, Isaacs JT, et al. Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in human prostate cancer. Clin Cancer Res. 2016;22:4651\u201363.","journal-title":"Clin Cancer Res"},{"key":"6115_CR23","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/annonc\/mdv282","volume":"26","author":"M Nakazawa","year":"2015","unstructured":"Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015;26:1859\u201365.","journal-title":"Ann Oncol"},{"key":"6115_CR24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/1078-0432.CCR-16-1070","volume":"23","author":"F Qu","year":"2017","unstructured":"Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, et al. Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res. 2017;23:726\u201334.","journal-title":"Clin Cancer Res"},{"key":"6115_CR25","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.eururo.2016.11.024","volume":"71","author":"HI Scher","year":"2017","unstructured":"Scher HI, Graf RP, Schreiber NA, McLaughlin B, Lu D, Louw J, et al. Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol. 2017;71:874\u201382.","journal-title":"Eur Urol"},{"key":"6115_CR26","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","volume":"2","author":"HI Scher","year":"2016","unstructured":"Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2:1441\u20139.","journal-title":"JAMA Oncol"},{"key":"6115_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.eururo.2016.03.049","volume":"70","author":"J Welti","year":"2016","unstructured":"Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, et al. Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur Urol. 2016;70:599\u2013608.","journal-title":"Eur Urol"},{"key":"6115_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.eururo.2017.08.009","volume":"73","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, et al. Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer. Eur Urol. 2018;73:727\u201335.","journal-title":"Eur Urol"},{"key":"6115_CR29","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1038\/onc.2013.284","volume":"33","author":"LL Liu","year":"2014","unstructured":"Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 2014;33:3140\u201350.","journal-title":"Oncogene"},{"key":"6115_CR30","doi-asserted-by":"publisher","first-page":"17492","DOI":"10.1073\/pnas.1308587110","volume":"110","author":"MD Nyquist","year":"2013","unstructured":"Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, et al. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci USA. 2013;110:17492\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6115_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16\u201322.","journal-title":"Cancer Res"},{"key":"6115_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761\u201372.","journal-title":"Nat Rev Cancer"},{"key":"6115_CR33","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nature10317","volume":"475","author":"FU Hartl","year":"2011","unstructured":"Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475:324\u201332.","journal-title":"Nature"},{"key":"6115_CR34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ccr.2008.08.002","volume":"14","author":"MV Powers","year":"2008","unstructured":"Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell. 2008;14:250\u201362.","journal-title":"Cancer Cell"},{"key":"6115_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/JME-08-0116","volume":"42","author":"E Meimaridou","year":"2009","unstructured":"Meimaridou E, Gooljar SB, Chapple JP. From hatching to dispatching: the multiple cellular roles of the Hsp70 molecular chaperone machinery. J Mol Endocrinol. 2009;42:1\u20139.","journal-title":"J Mol Endocrinol"},{"key":"6115_CR36","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1038\/s41467-018-07178-x","volume":"9","author":"C Liu","year":"2018","unstructured":"Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, et al. Proteostasis by STUB1\/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018;9:4700.","journal-title":"Nat Commun"},{"key":"6115_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12943-023-01773-3","volume":"22","author":"L Xiong","year":"2023","unstructured":"Xiong L, Liu HS, Zhou C, Yang X, Huang L, Jie HQ, et al. A novel protein encoded by circINSIG1 reprograms cholesterol metabolism by promoting the ubiquitin-dependent degradation of INSIG1 in colorectal cancer. Mol Cancer. 2023;22:72.","journal-title":"Mol Cancer"},{"key":"6115_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-022-01570-4","volume":"21","author":"Z Wang","year":"2022","unstructured":"Wang Z, Sun A, Yan A, Yao J, Huang H, Gao Z, et al. Circular RNA MTCL1 promotes advanced laryngeal squamous cell carcinoma progression by inhibiting C1QBP ubiquitin degradation and mediating beta-catenin activation. Mol Cancer. 2022;21:92.","journal-title":"Mol Cancer"},{"key":"6115_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-022-01495-y","volume":"21","author":"L Zheng","year":"2022","unstructured":"Zheng L, Liang H, Zhang Q, Shen Z, Sun Y, Zhao X, et al. circPTEN1, a circular RNA generated from PTEN, suppresses cancer progression through inhibition of TGF-beta\/Smad signaling. Mol Cancer. 2022;21:41.","journal-title":"Mol Cancer"},{"issue":"2004\u201317","key":"6115_CR40","volume":"162","author":"X Shi","year":"2022","unstructured":"Shi X, Yang J, Liu M, Zhang Y, Zhou Z, Luo W, et al. Circular RNA ANAPC7 inhibits tumor growth and muscle wasting via PHLPP2-AKT-TGF-beta signaling axis in pancreatic cancer. Gastroenterology. 2022;162(2004\u201317): e2.","journal-title":"Gastroenterology"},{"key":"6115_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206732","volume":"10","author":"R Chen","year":"2023","unstructured":"Chen R, Yang T, Jin B, Xu W, Yan Y, Wood N, et al. CircTmeff1 promotes muscle atrophy by interacting with TDP-43 and encoding a novel TMEFF1-339aa protein. Adv Sci. 2023;10: e2206732.","journal-title":"Adv Sci"},{"key":"6115_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12943-021-01480-x","volume":"21","author":"YZ Yu","year":"2022","unstructured":"Yu YZ, Lv DJ, Wang C, Song XL, Xie T, Wang T, et al. Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p. Mol Cancer. 2022;21:12.","journal-title":"Mol Cancer"},{"key":"6115_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12943-022-01630-9","volume":"21","author":"T Xie","year":"2022","unstructured":"Xie T, Fu DJ, Li ZM, Lv DJ, Song XL, Yu YZ, et al. CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322\/CCL20\/CCR6 signaling. Mol Cancer. 2022;21:173.","journal-title":"Mol Cancer"},{"key":"6115_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13046-022-02391-5","volume":"41","author":"L Ding","year":"2022","unstructured":"Ding L, Wang R, Zheng Q, Shen D, Wang H, Lu Z, et al. circPDE5A regulates prostate cancer metastasis via controlling WTAP-dependent N6-methyladenisine methylation of EIF3C mRNA. J Exp Clin Cancer Res. 2022;41:187.","journal-title":"J Exp Clin Cancer Res"},{"key":"6115_CR45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1158\/0008-5472.CAN-21-2988","volume":"82","author":"X Jiang","year":"2022","unstructured":"Jiang X, Guo S, Wang S, Zhang Y, Chen H, Wang Y, et al. EIF4A3-induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2\/c-Myc\/LDHA signaling. Cancer Res. 2022;82:831\u201345.","journal-title":"Cancer Res"},{"key":"6115_CR46","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","volume":"20","author":"C Liu","year":"2014","unstructured":"Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014;20:3198\u2013210.","journal-title":"Clin Cancer Res"},{"key":"6115_CR47","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41556-021-00639-4","volume":"23","author":"X Gao","year":"2021","unstructured":"Gao X, Xia X, Li F, Zhang M, Zhou H, Wu X, et al. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling. Nat Cell Biol. 2021;23:278\u201391.","journal-title":"Nat Cell Biol"},{"key":"6115_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12943-020-1135-7","volume":"19","author":"M Lei","year":"2020","unstructured":"Lei M, Zheng G, Ning Q, Zheng J, Dong D. Translation and functional roles of circular RNAs in human cancer. Mol Cancer. 2020;19:30.","journal-title":"Mol Cancer"},{"key":"6115_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12943-020-01183-9","volume":"19","author":"X Zheng","year":"2020","unstructured":"Zheng X, Huang M, Xing L, Yang R, Wang X, Jiang R, et al. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer. Mol Cancer. 2020;19:73.","journal-title":"Mol Cancer"},{"key":"6115_CR50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-023-01759-1","volume":"22","author":"Z Hu","year":"2023","unstructured":"Hu Z, Chen G, Zhao Y, Gao H, Li L, Yin Y, et al. Exosome-derived circCCAR1 promotes CD8+ T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Mol Cancer. 2023;22:55.","journal-title":"Mol Cancer"},{"key":"6115_CR51","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/neuonc\/noaa214","volume":"23","author":"Y Wei","year":"2021","unstructured":"Wei Y, Lu C, Zhou P, Zhao L, Lyu X, Yin J, et al. EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS\/MEK1\/ERK1-2 signaling. Neuro Oncol. 2021;23:611\u201324.","journal-title":"Neuro Oncol"},{"key":"6115_CR52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13046-022-02368-4","volume":"41","author":"M Yang","year":"2022","unstructured":"Yang M, Hu H, Wu S, Ding J, Yin B, Huang B, et al. EIF4A3-regulated circ_0087429 can reverse EMT and inhibit the progression of cervical cancer via miR-5003-3p-dependent upregulation of OGN expression. J Exp Clin Cancer Res. 2022;41:165.","journal-title":"J Exp Clin Cancer Res"},{"key":"6115_CR53","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1101\/gad.314856.118","volume":"32","author":"C Huang","year":"2018","unstructured":"Huang C, Liang D, Tatomer DC, Wilusz JE. A length-dependent evolutionarily conserved pathway controls nuclear export of circular RNAs. Genes Dev. 2018;32:639\u201344.","journal-title":"Genes Dev"},{"key":"6115_CR54","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol. 2023;41:5561\u20138.","journal-title":"J Clin Oncol"},{"key":"6115_CR55","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12916-022-02263-x","volume":"20","author":"X Qin","year":"2022","unstructured":"Qin X, Ji D, Gu W, Han W, Luo H, Du C, et al. Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I\/II trial. BMC Med. 2022;20:84.","journal-title":"BMC Med"},{"key":"6115_CR56","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.2017.76.4381","volume":"36","author":"RZ Szmulewitz","year":"2018","unstructured":"Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol. 2018;36:1389\u201395.","journal-title":"J Clin Oncol"},{"key":"6115_CR57","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdz397","volume":"30","author":"EJ Small","year":"2019","unstructured":"Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol. 2019;30:1813\u201320.","journal-title":"Ann Oncol"},{"key":"6115_CR58","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41467-021-21860-7","volume":"12","author":"Y He","year":"2021","unstructured":"He Y, Wei T, Ye Z, Orme JJ, Lin D, Sheng H, et al. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nat Commun. 2021;12:1521.","journal-title":"Nat Commun"},{"key":"6115_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updates. 2023;68: 100962.","journal-title":"Drug Resist Updates"},{"key":"6115_CR60","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1172\/JCI122819","volume":"129","author":"A Sharp","year":"2019","unstructured":"Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 2019;129:192\u2013208.","journal-title":"J Clin Invest"},{"key":"6115_CR61","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563\u201371.","journal-title":"J Clin Oncol"},{"key":"6115_CR62","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41418-020-0600-6","volume":"28","author":"D Zhang","year":"2021","unstructured":"Zhang D, Ni N, Wang Y, Tang Z, Gao H, Ju Y, et al. CircRNA-vgll3 promotes osteogenic differentiation of adipose-derived mesenchymal stem cells via modulating miRNA-dependent integrin alpha5 expression. Cell Death Differ. 2021;28:283\u2013302.","journal-title":"Cell Death Differ"},{"key":"6115_CR63","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13432","volume":"56","author":"C Zhao","year":"2023","unstructured":"Zhao C, Qian S, Tai Y, Guo Y, Tang C, Huang Z, et al. Proangiogenic role of circRNA-007371 in liver fibrosis. Cell Prolif. 2023;56: e13432.","journal-title":"Cell Prolif"},{"key":"6115_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2023.115226","volume":"228","author":"G Wang","year":"2023","unstructured":"Wang G, Cheng T, Yuan H, Zou F, Miao P, Jiao J. Tracing cellular interaction of circRNA-miRNA axis with Cu metal-organic framework supported DNA cascade assembly. Biosens Bioelectron. 2023;228: 115226.","journal-title":"Biosens Bioelectron"},{"key":"6115_CR65","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.7150\/ijbs.85063","volume":"19","author":"F Long","year":"2023","unstructured":"Long F, Li L, Xie C, Ma M, Wu Z, Lu Z, et al. Intergenic CircRNA Circ_0007379 inhibits colorectal cancer progression by modulating miR-320a biogenesis in a KSRP-dependent manner. Int J Biol Sci. 2023;19:3781\u2013803.","journal-title":"Int J Biol Sci"},{"key":"6115_CR66","doi-asserted-by":"publisher","first-page":"10739","DOI":"10.1038\/s41598-019-47189-2","volume":"9","author":"J Greene","year":"2019","unstructured":"Greene J, Baird AM, Casey O, Brady L, Blackshields G, Lim M, et al. Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep. 2019;9:10739.","journal-title":"Sci Rep"},{"key":"6115_CR67","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41420-022-00898-6","volume":"8","author":"L Chen","year":"2022","unstructured":"Chen L, Sun Y, Tang M, Wu D, Xiang Z, Huang CP, et al. High-dose-androgen-induced autophagic cell death to suppress the enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2\/miRNA-198\/AMBRA1 signaling. Cell Death Discov. 2022;8:128.","journal-title":"Cell Death Discov"},{"key":"6115_CR68","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41419-018-1048-1","volume":"10","author":"G Wu","year":"2019","unstructured":"Wu G, Sun Y, Xiang Z, Wang K, Liu B, Xiao G, et al. Preclinical study using circular RNA 17 and micro RNA 181c\u20135p to suppress the enzalutamide-resistant prostate cancer progression. Cell Death Dis. 2019;10:37.","journal-title":"Cell Death Dis"},{"key":"6115_CR69","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ymthe.2021.08.026","volume":"30","author":"Y Li","year":"2022","unstructured":"Li Y, Wang Z, Su P, Liang Y, Li Z, Zhang H, et al. circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt\/beta-catenin pathway. Mol Ther. 2022;30:415\u201330.","journal-title":"Mol Ther"},{"key":"6115_CR70","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ymthe.2021.08.027","volume":"30","author":"P Li","year":"2022","unstructured":"Li P, Song R, Yin F, Liu M, Liu H, Ma S, et al. circMRPS35 promotes malignant progression and cisplatin resistance in hepatocellular carcinoma. Mol Ther. 2022;30:431\u201347.","journal-title":"Mol Ther"},{"key":"6115_CR71","doi-asserted-by":"publisher","first-page":"2001701","DOI":"10.1002\/advs.202001701","volume":"8","author":"Y Li","year":"2021","unstructured":"Li Y, Chen B, Zhao J, Li Q, Chen S, Guo T, et al. HNRNPL circularizes ARHGAP35 to produce an oncogenic protein. Adv Sci. 2021;8:2001701.","journal-title":"Adv Sci"},{"key":"6115_CR72","doi-asserted-by":"publisher","first-page":"34985","DOI":"10.1038\/srep34985","volume":"6","author":"X Chen","year":"2016","unstructured":"Chen X, Han P, Zhou T, Guo X, Song X, Li Y. circRNADb: a comprehensive database for human circular RNAs with protein-coding annotations. Sci Rep. 2016;6:34985.","journal-title":"Sci Rep"},{"key":"6115_CR73","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.bbapap.2006.03.013","volume":"1764","author":"I Rees","year":"2006","unstructured":"Rees I, Lee S, Kim H, Tsai FT. The E3 ubiquitin ligase CHIP binds the androgen receptor in a phosphorylation-dependent manner. Biochim Biophys Acta. 2006;1764:1073\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"6115_CR74","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/emboj.2010.337","volume":"30","author":"P Chymkowitch","year":"2011","unstructured":"Chymkowitch P, Le May N, Charneau P, Compe E, Egly JM. The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin\/proteasome process. EMBO J. 2011;30:468\u201379.","journal-title":"EMBO J"},{"key":"6115_CR75","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/onc.2012.561","volume":"33","author":"S Sarkar","year":"2014","unstructured":"Sarkar S, Brautigan DL, Parsons SJ, Larner JM. Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells. Oncogene. 2014;33:26\u201333.","journal-title":"Oncogene"},{"key":"6115_CR76","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cell.2014.05.039","volume":"158","author":"M Taipale","year":"2014","unstructured":"Taipale M, Tucker G, Peng J, Krykbaeva I, Lin ZY, Larsen B, et al. A quantitative chaperone interaction network reveals the architecture of cellular protein homeostasis pathways. Cell. 2014;158:434\u201348.","journal-title":"Cell"},{"key":"6115_CR77","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1091\/mbc.e13-01-0010","volume":"24","author":"A Shiber","year":"2013","unstructured":"Shiber A, Breuer W, Brandeis M, Ravid T. Ubiquitin conjugation triggers misfolded protein sequestration into quality control foci when Hsp70 chaperone levels are limiting. Mol Biol Cell. 2013;24:2076\u201387.","journal-title":"Mol Biol Cell"},{"key":"6115_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005178","volume":"11","author":"LZ Peters","year":"2015","unstructured":"Peters LZ, Karmon O, David-Kadoch G, Hazan R, Yu T, Glickman MH, et al. The protein quality control machinery regulates its misassembled proteasome subunits. PLoS Genet. 2015;11: e1005178.","journal-title":"PLoS Genet"},{"key":"6115_CR79","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nature04600","volume":"440","author":"SB Qian","year":"2006","unstructured":"Qian SB, McDonough H, Boellmann F, Cyr DM, Patterson C. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature. 2006;440:551\u20135.","journal-title":"Nature"},{"key":"6115_CR80","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/jnci\/85.7.570","volume":"85","author":"DR Ciocca","year":"1993","unstructured":"Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst. 1993;85:570\u20134.","journal-title":"J Natl Cancer Inst"},{"key":"6115_CR81","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1046\/j.1440-1746.2003.03011.x","volume":"18","author":"TS Hwang","year":"2003","unstructured":"Hwang TS, Han HS, Choi HK, Lee YJ, Kim YJ, Han MY, et al. Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J Gastroenterol Hepatol. 2003;18:690\u2013700.","journal-title":"J Gastroenterol Hepatol"},{"key":"6115_CR82","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1379\/CSC-44R.1","volume":"10","author":"D Tang","year":"2005","unstructured":"Tang D, Khaleque MA, Jones EL, Theriault JR, Li C, Wong WH, et al. Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones. 2005;10:46\u201358.","journal-title":"Cell Stress Chaperones"},{"key":"6115_CR83","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.cell.2015.02.014","volume":"160","author":"SJ Conn","year":"2015","unstructured":"Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160:1125\u201334.","journal-title":"Cell"},{"key":"6115_CR84","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.molcel.2015.03.027","volume":"58","author":"A Rybak-Wolf","year":"2015","unstructured":"Rybak-Wolf A, Stottmeister C, Glazar P, Jens M, Pino N, Giusti S, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58:870\u201385.","journal-title":"Mol Cell"},{"key":"6115_CR85","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12943-018-0911-0","volume":"17","author":"R Wang","year":"2018","unstructured":"Wang R, Zhang S, Chen X, Li N, Li J, Jia R, et al. EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes glioblastoma multiforme cell tumorigenesis. Mol Cancer. 2018;17:166.","journal-title":"Mol Cancer"},{"issue":"4174\u201389","key":"6115_CR86","volume":"83","author":"I Tapescu","year":"2023","unstructured":"Tapescu I, Taschuk F, Pokharel SM, Zginnyk O, Ferretti M, Bailer PF, et al. The RNA helicase DDX39A binds a conserved structure in chikungunya virus RNA to control infection. Mol Cell. 2023;83(4174\u201389): e7.","journal-title":"Mol Cell"},{"key":"6115_CR87","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1101\/gad.316216.118","volume":"32","author":"Y Wan","year":"2018","unstructured":"Wan Y, Hopper AK. Size matters: conserved proteins function in length-dependent nuclear export of circular RNAs. Genes Dev. 2018;32:600\u20131.","journal-title":"Genes Dev"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06115-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06115-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06115-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T23:09:47Z","timestamp":1737587387000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06115-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6115"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06115-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5114963\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experimental procedures involving mice were carried out as prescribed by the National Guidelines for Animal Usage in Research (China) and were approved by the Institutional Animal Care and Use Committee of Xuzhou Medical University (202309T023). This study was conducted following approval by the Institutional Animal Care and Use Committee of Xuzhou Medical University (202309T023). All treatments were administered in accordance with the guidelines established by the committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}